# Veterinary Pain Management Market

> Global Veterinary Pain Management Market Research Report By Product Type (Non-Steroidal Anti-Inflammatory Drugs, Opioids, Analgesics, Adjuvant Analgesics), By Animal Type (Dogs, Cats, Horses, Livestock), By Route of Administration (Oral, Injections, Transdermal, Topical), By End User (Veterinary Hospitals, Clinics, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.2%
- **2025:** USD 1.85 Billion
- **2035:** USD 3.37 Billion
- **Key Players:** Zoetis, Boehringer Ingelheim, Elanco Animal Health, Merck Animal Health, Dechra Pharmaceuticals, Ceva Santé Animale, Vetoquinol, Virbac

**Report ID:** MRFR/HC/4505-CR · **Pages:** 200 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** October 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/veterinary-pain-management-market-5961

---

## Market Summary

As per Market Research Future analysis, the Veterinary Pain Management Market was estimated at 2.11 USD Billion in 2024. The Veterinary Pain Management industry is projected to grow from 2.246 USD Billion in 2025 to 4.184 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.42% during the forecast period 2025 - 2035

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Pet humanization and rising care spend | +1.4% | Global; North America core | Long-term | [1][2] |
| Osteoarthritis burden and anti-NGF biologics | +1.2% | North America, Europe | Medium-term | [6] |
| Livestock welfare regulation | +0.9% | Europe, North America | Long-term | [5][9] |
| Multimodal surgical analgesia standards | +0.8% | Global | Short-term | [6][7] |
| Pet insurance penetration | +0.7% | North America, Europe | Medium-term | [8] |
| Veterinary infrastructure growth in Asia | +0.6% | Asia-Pacific | Long-term | [20] |
| Telehealth and home-administered regimens | +0.5% | North America, Europe | Short-term | [13] |

### Pet Humanization and Rising Care Spend

Dogs and cats are increasingly treated as part of the family by their owners, who pay for their care accordingly. Veterinary care and goods are among the fastest-growing areas, according to the American Pet Products Association, which projects that the U.S. pet business will spend approximately USD 152 billion in 2024 [1]. Nearly half of American families have dogs, according to AVMA survey statistics [2]. Patients with longer lifespans are more likely to reach the age at which they require long-term care for conditions including arthritis, dental disease, and cancer pain.

### Osteoarthritis Burden and Anti-NGF Biologics

According to studies included in the AAHA guidelines, up to 40% of dogs may have osteoarthritis symptoms [6]. With the FDA's 2023 approval of bedinvetmab, a monthly injectable class was established, shifting revenue from cheap generics to high-end biologics . The same technique is extended to cats with feline frunevetmab, a species with limited safe long-term NSAID alternatives. Recurring visits increase clinic income per patient in the veterinary pain management market.

### Livestock Welfare Regulation

Regulation (EU) 2019/6 tightened controls on veterinary medicines across 27 member states, while EU welfare rules increasingly expect analgesia for castration, dehorning and tail docking [5]. The World Organisation for [Animal Health](https://www.marketresearchfuture.com/reports/animal-health-market-7163) codifies pain mitigation in its terrestrial welfare chapters, guiding 183 member countries [9]. Retail-led audit schemes now translate those principles into purchasing requirements, sustaining bulk NSAID demand from dairy and swine producers.

### Multimodal Surgical Analgesia Standards

Guidelines from AAHA and the WSAVA Global Pain Council recommend combining NSAIDs, local blocks, opioids and alpha-2 agonists around surgery [6][7]. Accreditation programs and continuing education embed these protocols in routine spay, neuter and orthopedic cases. Post-surgical pet pain management now often includes a take-home NSAID plus a long-acting local anesthetic, adding two to three products per procedure compared with single-agent protocols a decade ago.

### Pet Insurance Penetration

The North American Pet Health Insurance Association reported more than 6 million insured pets in 2023, with gross written premiums growing at double-digit rates [8]. Insured owners accept higher-cost biologics and device sessions because reimbursement offsets out-of-pocket spend. Several European markets, including the UK and Sweden, already show far higher penetration. Insurers that cover chronic conditions directly enlarge the paying pool for long-term pain therapy.

### Veterinary Infrastructure Growth in Asia

China's urban pet consumption market exceeded CNY 300 billion in 2024, according to industry white paper data [20]. Chain hospitals in tier-one and tier-two cities are standardizing surgical analgesia and importing branded NSAIDs. India's companion animal clinic base is expanding from a small foundation. These trends make Asia-Pacific the main volume engine for the Veterinary Pain Management Market through 2035.

### Telehealth and Home-Administered Regimens

Telemedicine platforms now handle triage, refill authorization and follow-up for chronic pain patients. Oral chewable NSAIDs and transdermal buprenorphine let owners administer therapy without clinic visits . Large practice groups report higher adherence when refills ship automatically [13]. The shift moves part of revenue from in-clinic dispensing to e-pharmacy channels, while keeping veterinarians in a supervisory prescribing role.

## Restraints

## Restraints Impact Analysis

Restraint values are directional estimates of downward pressure on growth. They overlap with drivers and with each other, so they should not be subtracted directly from the forecast CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Adverse event and safety concerns | −0.7% | Global | Short-term |  |
| High cost in price-sensitive markets | −0.6% | Asia-Pacific, South America, Middle East and Africa | Long-term | [21] |
| Controlled-substance rules for opioids | −0.5% | North America, Europe | Medium-term | [11] |
| Food-animal residue and withdrawal limits | −0.4% | Europe, North America | Medium-term | [18] |
| Veterinary workforce shortages | −0.4% | Global | Long-term | [12] |

### Adverse Event and Safety Concerns

The FDA amended the label of bedinvetmab and sent a letter to veterinarians in December 2024 regarding adverse events that were reported . Long-term usage of NSAIDs in elderly animals is already restricted due to owner concerns about their gastrointestinal and renal consequences. Switching to new classes might be slowed by safety headlines, especially when social media magnifies individual cases.

### High Cost in Price-Sensitive Markets

Owners pay multiple times as much for monthly biologic injections as they do for generic meloxicam. Insurance is uncommon and out-of-pocket payments predominate throughout Asia-Pacific, South America, and much of Africa [21]. Premium treatments are only available in metropolitan specialist clinics due to price sensitivity. In order to increase volume without reducing margins, suppliers must provide tiered portfolios.

### Controlled-Substance Rules for Opioids

Veterinary opioids fall under the U.S. Controlled Substances Act, which requires DEA registration, secure storage and detailed logs [11]. Diversion concerns linked to the human opioid crisis have pushed many clinics to reduce stocked quantities. Administrative burden steers prescribers toward non-controlled alternatives, restraining growth in the opioid sub-segment.

### Food-Animal Residue and Withdrawal Limits

EU maximum residue limits under Regulation (EC) 470/2009 constrain which molecules can be used in food-producing animals [18]. In the U.S., a transdermal flunixin product approved in 2017 remains the first FDA-approved drug for pain control in cattle . Few approved options and long withdrawal periods slow adoption among producers.

### Veterinary Workforce Shortages

Mars Veterinary Health has projected a U.S. shortfall of nearly 15,000 companion-animal veterinarians by 2030 [12]. Short-staffed clinics have less time for structured pain scoring, so chronic pain often goes unrecognized. Rural livestock practices face even sharper gaps, limiting on-farm analgesic administration.

## Opportunities

## Veterinary Pain Management Market Opportunities

### Cannabinoid-Based Therapeutics

Cannabinoid products hold a small share today but grow at the fastest rate of any drug sub-segment. Regulatory pathways remain unsettled in most markets, so the first supplier to secure a formal approval with species-specific pharmacokinetic data could set the category standard. University partnerships already generate safety data in dogs and cats, lowering development risk.

### Emerging-Market Clinic Networks

India, Brazil and Southeast Asia combine rising pet ownership with low treatment penetration. Affordable generic NSAIDs packaged for chain clinics, combined with training on pain scoring, offer a volume entry point. Local manufacturing partnerships can cut landed costs and ease registration timelines under national drug regulators.

### Data-Driven Subscription Models

Wearable activity monitors can feed mobility data to veterinarian dashboards, flagging breakthrough pain before owners notice it. Suppliers that bundle monthly injections, remote check-ins and outcome tracking can monetize longitudinal data. Aggregated, anonymized outcome datasets also hold value for label expansions and payer negotiations in the Veterinary Pain Management Market.

### Long-Acting Formulations for Livestock

Producers want analgesia that fits existing handling events, such as a single injection or pour-on at processing. Long-acting formulations with short withdrawal periods would remove a key adoption barrier. Retail welfare audits create a ready buyer base, especially in European dairy and North American beef supply chains.

### Devices for Geriatric and NSAID-Intolerant Patients

Older pets with kidney or liver disease often cannot take NSAIDs long term. Laser and electromagnetic devices give clinics a non-drug option they can bill per session, broadening companion animal pain care for patients with limited pharmacological choices. Home-use electromagnetic devices also open a direct-to-owner channel that grows the Veterinary Pain Management Market outside clinic walls.

## Future Outlook

## Veterinary Pain Management Market Future Outlook

### Biologics and Long-Acting Molecules

Monoclonal antibodies will likely extend beyond NGF to other pain pathways, with monthly or quarterly dosing. Combined with liposomal local anesthetics, these products move the Veterinary Pain Management Market toward fewer, higher-value administrations. Zoetis has reported its osteoarthritis pain franchise as a leading growth contributor [13], signaling sustained investment in the class.

### AI-Enabled Pain Assessment

Machine-learning models trained on facial grimace scales and gait data can score pain from smartphone video. Wearables add continuous activity tracking. These tools address the workforce gap [12] by giving clinicians objective data without long exam times, and they support remote titration of therapy.

### Practice Consolidation and Platform Economics

Corporate groups and private equity owners continue to acquire independent clinics and suppliers, as shown by EQT's 2024 acquisition of Dechra [16]. Consolidated buyers negotiate formulary contracts and favor suppliers that offer bundled portfolios, digital tools and training, raising barriers for single-product companies.

### Livestock Welfare and Sustainability Reporting

The OECD-FAO Agricultural Outlook projects continued growth in global meat consumption through 2033 [19]. Food companies increasingly report animal welfare metrics alongside environmental data. Documented analgesia at painful procedures becomes an auditable sustainability claim, which supports long-term demand in the Veterinary Pain Management Market from large producers.

## Segment Insights

## Veterinary Pain Management Market Segmentation

### By Product (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Drugs | 85.4% share (2025) | First-line therapy across species |
| Drugs — NSAIDs | 46.2% share (2025) | Low cost and broad label coverage |
| Drugs — Opioids | USD 0.31 Billion (2025) | Acute surgical and trauma pain |
| Drugs — Local Anesthetics | 6.9% CAGR (2026–2035) | Long-acting liposomal formulations |
| Drugs — Alpha-2 Agonists | USD 0.13 Billion (2025) | Sedation and large animal procedures |
| Drugs — Cannabinoid-based Therapeutics | 11.8% CAGR (2026–2035) | Chronic pain resistant to other classes |
| Devices | 6.5% CAGR (2026–2035) | NSAID-intolerant and geriatric patients |
| Devices — Laser Therapy | 9.7% share (2025) | Per-session clinic billing |
| Devices — Electromagnetic Therapy | 6.9% CAGR (2026–2035) | Equine and home-use applications |

Within the Veterinary Pain Management Market, Drugs lead at 85.4% share, anchored by NSAIDs such as meloxicam and carprofen. Opioids retain an acute-care role despite diversion controls, while long-acting local anesthetics reduce readmissions after surgery. Alpha-2 agonists serve large animal sedation, and Cannabinoid-based Therapeutics grow fastest from a small base. Devices grow at 6.5% CAGR, with Laser Therapy used in clinics and Electromagnetic Therapy gaining equine and home use.

### By Animal Type (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Companion Animals | 7.3% CAGR (2026–2035) | Biologic osteoarthritis therapy |
| Livestock | 51.6% share (2025) | Welfare audits and herd-scale procedures |

Livestock holds 51.6% of the Veterinary Pain Management Market by value, reflecting herd-scale analgesia at castration, dehorning and lameness treatment. Buyers focus on cost per head and withdrawal periods, favoring generic NSAIDs in bulk packs. Companion Animals grow faster at 7.3% CAGR because dog and cat owners pay for biologics and device sessions that prioritize quality of life over minimum effective care.

### By End User (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Veterinary Hospitals & Clinics | 57.1% share (2025) | Surgical volumes and in-clinic injections |
| Homecare Settings | 6.9% CAGR (2026–2035) | Telehealth refills and transdermal products |
| Academic & Research Institutes | USD 0.09 Billion (2025) | Clinical validation of new modalities |

Across the Veterinary Pain Management Market, Veterinary Hospitals & Clinics hold a 57.1% share because surgery, injections and device sessions occur on site. Homecare Settings grow fastest at 6.9% CAGR as courier-delivered refills, chewable NSAIDs and transdermal buprenorphine reduce clinic visits. Academic & Research Institutes are a small revenue pool but validate new tools, including machine-learning grimace scales and species-specific cannabinoid pharmacokinetics.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.2% share | Biologics, insurance-funded chronic care, telehealth refills |
| Europe | 27.6% share | Livestock welfare compliance, EU pharmacovigilance |
| Asia-Pacific | 7.4% CAGR | Chain hospital expansion, imported branded NSAIDs |
| South America | USD 0.11 Billion | Beef and dairy herd analgesia, urban pet clinics |
| Middle East and Africa | 6.6% CAGR | Premium clinics in GCC, equine care |
| Total | USD 1.85 Billion | — |

The Veterinary Pain Management Market shows a clear regional hierarchy. North America leads on biologic adoption and insurance, Europe on livestock welfare regulation, and Asia-Pacific on growth.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 87.5% share of region | Biologic uptake and pet insurance growth |
| Canada | 6.0% CAGR (2026–2035) | Expanding corporate practice networks |

The United States anchors the region with the largest base of insured pets and the earliest launches of anti-NGF antibodies [8]. Corporate consolidators run standardized multimodal protocols across thousands of hospitals, which speeds adoption of new products once added to formularies. Canada follows similar clinical patterns, with Health Canada's Veterinary Drugs Directorate approving many of the same molecules a few quarters after U.S. launch.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 23.8% share of region | Large companion and swine populations |
| United Kingdom | USD 0.10 Billion | High insurance penetration |
| France | 5.7% CAGR (2026–2035) | Dairy welfare audits |
| Italy | 11.9% share of region | Rising companion animal ownership |
| Spain | USD 0.04 Billion | Pig sector welfare requirements |
| Rest of Europe | 5.2% CAGR (2026–2035) | Nordic welfare standards |

European demand reflects both companion and livestock use. Regulation (EU) 2019/6 harmonized authorization and post-market surveillance across member states, raising compliance costs but also easing multi-country launches [5]. Germany and Spain carry large swine sectors where analgesia at castration is increasingly expected, while the United Kingdom's insurance market supports premium companion therapies.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | USD 0.12 Billion | Urban pet consumption growth |
| India | 9.6% CAGR (2026–2035) | Clinic expansion from a low base |
| Japan | 21.5% share of region | Aging pet population |
| South Korea | 7.9% CAGR (2026–2035) | High spend per pet |
| Australia | USD 0.05 Billion | Livestock welfare and companion care |
| Rest of Asia-Pacific | 6.8% CAGR (2026–2035) | Southeast Asian clinic chains |

Asia-Pacific is the growth engine of the Veterinary Pain Management Market. China's chain hospitals are adopting Western surgical protocols, and urban pet spending passed CNY 300 billion in 2024 [20]. Japan's mature, aging pet population supports chronic therapies, while Australia combines strong companion demand with mulesing and castration welfare requirements for sheep and cattle.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 62.4% share of region | Large pet population and beef herd |
| Argentina | 6.3% CAGR (2026–2035) | Cattle sector modernization |
| Rest of South America | USD 0.02 Billion | Urban clinic growth |

Brazil dominates regional spending, with one of the world's largest dog and cat populations and a cattle herd exceeding 200 million head [19]. Export-oriented beef producers face buyer welfare audits that encourage analgesia at processing. Argentina's growth tracks cattle sector investment, though currency volatility affects imported product pricing.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | USD 0.03 Billion | Premium companion and equine clinics |
| South Africa | 28.7% share of region | Established veterinary infrastructure |
| Rest of Middle East and Africa | 6.2% CAGR (2026–2035) | Gradual clinic expansion |

Gulf states support high-value equine and companion care, with specialist hospitals in the UAE and Saudi Arabia importing branded therapies. South Africa holds the most developed veterinary network in sub-Saharan Africa. Elsewhere, limited clinic density and cost sensitivity keep demand focused on low-cost NSAIDs for livestock.

## Competitive Benchmarking

## Competitive Benchmarking

The Veterinary Pain Management Market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of roughly 1,100–1,300. The top five suppliers hold an estimated 55–60% of revenue, led by multinational animal health companies with broad NSAID and biologic portfolios. A long tail of generic manufacturers and device makers competes on price, regional reach and niche applications.

| Company | Est. Revenue Share Range | Key Offerings for Veterinary Pain Management Market | Strategic Positioning |
| --- | --- | --- | --- |
| Zoetis | ~18–22% | Librela, Solensia, Rimadyl | Biologic leader in osteoarthritis pain |
| Boehringer Ingelheim | ~11–14% | Metacam, Previcox, Equioxx | Broad NSAID franchise across species |
| Elanco Animal Health | ~10–13% | Galliprant, Onsior, Nocita, Zorbium | Differentiated companion animal molecules |
| Merck Animal Health | ~6–9% | Banamine, Banamine Transdermal | Livestock analgesia focus |
| Dechra Pharmaceuticals | ~5–7% | Opioid, anesthetic and NSAID portfolio | Specialist clinic supplier under EQT ownership |
| Ceva Santé Animale | ~4–6% | Buprenorphine and meloxicam products | Strong European and emerging-market reach |
| Vetoquinol | ~3–5% | Cimalgex and NSAID range | Mid-size specialist in pain and mobility |
| Virbac | ~2–4% | Generic NSAIDs | Cost-competitive portfolio in Asia and Latin America |
| Norbrook Laboratories | ~2–3% | Loxicom (meloxicam) | Generic manufacturing scale |
| Companion Animal Health (LiteCure) | ~1–2% | Class IV therapy lasers | Leading veterinary laser device supplier |

## Recent News & Developments

## Recent News & Developments

- U.S. FDA (May 2023): Approved bedinvetmab, the first monoclonal antibody for controlling osteoarthritis pain in dogs, opening a premium biologic class
- U.S. FDA (September 2023): Animal Drug User Fee Act reauthorization (ADUFA V) took effect, funding review timelines for new animal drugs through 2028
- EQT (January 2024): Completed its acquisition of Dechra Pharmaceuticals, consolidating a major specialist analgesic and anesthetic supplier under private ownership [16]
- Zoetis (2024): Expanded Librela and Solensia into additional international markets, broadening the anti-NGF footprint [13]
- U.S. FDA (December 2024): Issued a letter to veterinarians on adverse events reported with Librela and updated product labeling, a pharmacovigilance milestone for the Veterinary Pain Management Market
- Zoetis (February 2025): Reported its osteoarthritis pain franchise among its fastest-growing product lines in full-year 2024 results [13]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Pain management drugs and devices for companion animals and livestock, sold through veterinary hospitals and clinics, homecare channels and academic and research institutes |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 1.85 Billion |
| Market Size in 2035 | USD 3.37 Billion |
| CAGR (2026–2035) | 6.2% |
| Fastest Growing Segments | Cannabinoid-based Therapeutics (11.8% CAGR); Companion Animals (7.3% CAGR); Homecare Settings (6.9% CAGR); Devices (6.5% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Zoetis, Boehringer Ingelheim, Elanco Animal Health, Merck Animal Health, Dechra Pharmaceuticals, Ceva Santé Animale, Vetoquinol, Virbac, Norbrook Laboratories, Companion Animal Health (LiteCure) |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should investors assess pipeline risk in the Veterinary Pain Management Market?**
A: Track post-approval pharmacovigilance as closely as approval milestones. Anti-NGF antibodies showed that adverse-event reporting can prompt label changes within two years of launch [4].

**Q: What procurement criteria do large veterinary practice groups apply to analgesics?**
A: Corporate groups favor multi-product suppliers offering volume rebates, logistics support and staff training. Single-molecule vendors usually win only with a clear clinical advantage or lower cost per treated patient [13].

**Q: How do compounded analgesics compete with approved products?**
A: FDA Guidance #256, finalized in 2022, limits compounding from bulk drug substances when approved drugs fit the need. Compounded formulations still fill gaps for feline and exotic patients without suitable approved dosage forms [23].

**Q: Which equine pain products attract investment in the Veterinary Pain Management Market?**
A: COX-2 selective firocoxib formulations lead equine NSAID use. Competition rules restrict analgesics around events, so detection-time data has become part of product positioning [15].

**Q: How are chronic pain therapies integrated into wellness plans?**
A: Practices bundle monthly injections, exams and diagnostics into membership plans. The model improves adherence and smooths owner spending but requires recurring-billing software [8].

**Q: What role do exotic animals play in the Veterinary Pain Management Market?**
A: Exotics remain a small revenue pool because few analgesics carry labeled doses for birds, reptiles or small mammals. U.S. veterinarians rely on extra-label use under AMDUCA [24].

**Q: How does generic competition affect NSAID pricing?**
A: Generic carprofen and meloxicam have compressed NSAID prices across mature markets. Branded suppliers respond with palatable chewables, injectables and combination packs [14].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/veterinary-pain-management-market-5961*